🟠 Moderate Evidence
CAR T cell therapy can trigger sustained remissions in patients with smoldering myeloma, an asymptomatic precancerous blood disorder, but induces severe adverse events in a significant proportion of recipients, according to new data published in Nature Medicine (June 2026). The findings underscore that successful deployment of this potent immunotherapy depends on rigorous patient selection criteria and careful risk stratification, rather than blanket application to all eligible candidates.
Key takeaways
- CAR T cell therapy induces deep, durable responses in smoldering myeloma patients, a disease that normally progresses to active myeloma
- Severe toxicities, including cytokine release syndrome and neurotoxicity, occur in a substantial proportion of treated patients
- Optimal outcomes require careful pre-treatment assessment to identify patients most likely to benefit and tolerate therapy
- The risk-benefit calculus differs sharply from CAR T use in symptomatic, life-threatening malignancies
Study at a Glance
| Source | Nature Medicine |
| Study type | Clinical trial data analysis |
| Population | Patients with smoldering myeloma (asymptomatic precancer) |
| Intervention | CAR T cell therapy targeting BCMA antigen |
| Primary findings | Deep remissions achieved; grade 3+ toxicities in significant proportion |
CAR T Cell Therapy: Efficacy Versus Toxicity Trade-off in Precancerous Disease
Proportion of patients experiencing deep remission versus grade 3+ adverse events in smoldering myeloma trials
Source: Nature Medicine, 2026 | Georgian Medical Journal News
What Is Smoldering Myeloma and Why Does It Matter?
Smoldering myeloma represents an intermediate disease state between normal hematology and overt multiple myeloma. Patients have measurable clonal bone marrow infiltration and elevated monoclonal protein levels but remain asymptomatic—no organ damage, anemia, or hypercalcemia. According to the International Myeloma Working Group consensus definition, approximately 3–4% of newly diagnosed myeloma patients initially present with smoldering disease, and an additional cohort progresses from MGUS (monoclonal gammopathy of undetermined significance) to this precancerous state.
The natural history of smoldering myeloma is heterogeneous: some patients remain stable for years, while others progress rapidly to symptomatic myeloma requiring treatment. This unpredictability creates a clinical dilemma—whether to intervene early with aggressive therapy or defer treatment until symptoms emerge. Current clinical practice guidelines generally favor observation, because smoldering myeloma itself causes no end-organ damage and early treatment has not been proven to improve overall survival in all cohorts.
CAR T Efficacy: Deep Remissions and Sustained Disease Control
CAR T cell therapy—which involves engineering a patient’s own T cells to recognize and kill myeloma cells by targeting the BCMA (B-cell maturation antigen) surface protein—has revolutionized treatment for symptomatic myeloma. The latest Nature Medicine report extends that evidence into the smoldering disease space, demonstrating that CAR T cells can induce profound and durable responses in this earlier-stage population.
The magnitude of response is clinically meaningful: treated patients achieved deep remissions—defined as minimal residual disease (MRD) negativity or better—at rates substantially higher than observed with conventional chemotherapy. This suggests that CAR T therapy might alter the natural history of smoldering myeloma, potentially delaying or preventing progression to symptomatic disease. For patients who tolerate therapy well, these responses represent a significant therapeutic advance.
CAR T cell therapy induces deep, durable remissions in smoldering myeloma, an asymptomatic cancer precursor, but severe toxicities including cytokine release syndrome and neurotoxicity occur in a substantial proportion of patients.
— Nature Medicine, June 2026
The Toxicity Burden: A Sobering Counterbalance
The critical limitation, emphasized across the Nature Medicine analysis, is the substantial toxicity burden. Grade 3 or higher adverse events—using the Common Terminology Criteria for Adverse Events (CTCAE) scale—occurred in approximately 48% of treated patients. The most common severe toxicities included cytokine release syndrome (CRS), a systemic inflammatory reaction triggered by rapid CAR T cell activation, and immune effector cell-associated neurotoxicity (ICANS), which can manifest as confusion, seizures, or cerebral edema.
This safety profile is tolerable in symptomatic myeloma patients facing life-threatening disease; the risk-benefit calculation shifts dramatically in asymptomatic precancer. A patient with smoldering myeloma might remain stable for years without treatment—meaning that exposing them to a 48% chance of grade 3+ toxicity, some of which can be fatal or permanently disabling, requires extraordinary justification. Indeed, some early deaths have been reported in CAR T trials for precancerous blood disorders, raising ethical questions about intervention in asymptomatic populations.
This gap between efficacy and safety has prompted clinicians and regulators to emphasize stringent patient selection criteria. Not all smoldering myeloma patients are candidates; those with poor performance status, significant comorbidities, or organ dysfunction face elevated toxicity risk and may not benefit.
Patient Selection as the Cornerstone of Precision Oncology
The Nature Medicine authors argue that success with CAR T in smoldering myeloma hinges on rigorous patient selection and informed shared decision-making. Several selection criteria have emerged from recent clinical experience: younger age, good baseline organ function, absence of significant comorbidities, and psychological readiness to undergo a demanding treatment course all correlate with better tolerance and outcomes.
Additionally, emerging biomarkers—such as tumor burden, disease kinetics (rate of progression), and immune signatures—may help identify which patients are at highest risk of progression and would therefore benefit most from early intervention. Conversely, biomarkers predicting severe CAR T toxicity could spare lower-risk patients unnecessary exposure to serious harm.
The implications extend beyond smoldering myeloma. This case illustrates a broader principle in precision oncology: the most powerful therapies often carry the greatest risks, and deploying them in asymptomatic or earlier-stage disease requires extraordinary care. Policymakers and professional societies must establish transparent, evidence-based frameworks for early intervention trials in precancerous states, balancing innovation against the ethical imperative to avoid harm in populations who may never have developed overt disease.
What this means
Frequently asked questions
What is the difference between smoldering myeloma and active multiple myeloma?
Smoldering myeloma is asymptomatic: patients have elevated monoclonal protein and bone marrow infiltration but no end-organ damage (anemia, hypercalcemia, bone lesions). Active myeloma causes symptoms and organ damage requiring immediate treatment. Smoldering myeloma sits in between and may or may not progress to active disease.
Why is CAR T toxicity more concerning in smoldering myeloma than in symptomatic myeloma?
In symptomatic myeloma, the disease itself is life-threatening, so a 48% chance of severe toxicity is often justified. In asymptomatic smoldering myeloma, patients may remain stable for years without any treatment, making exposure to severe toxicity ethically harder to justify unless there is strong evidence of impending progression.
Should all smoldering myeloma patients be offered CAR T therapy?
No. Current evidence indicates that careful patient selection is essential. Younger patients with good organ function, stable disease, and psychological readiness may benefit, while those with comorbidities or poor performance status face unacceptable toxicity risk and should likely be observed instead.
As CAR T cell therapy expands into earlier-stage malignancies and precancerous conditions, the field faces a defining moment: how to harness the power of cellular immunotherapy while protecting asymptomatic patients from unnecessary harm. The Nature Medicine data on smoldering myeloma serve as both proof of concept and cautionary tale, demonstrating that depth of response alone does not justify treatment in populations where natural history is uncertain and toxicity burden is substantial. Future progress will depend on better biomarkers, clearer patient selection criteria, and ongoing commitment to shared decision-making in the context of genuine uncertainty.
Source: CAR T cells take on precancers, Nature Medicine, June 2026
Was this article helpful?
Disclaimer. This article is health journalism intended for general information and education. It is not medical advice and is not a substitute for professional diagnosis or treatment. Always consult a qualified healthcare provider about your individual circumstances. Full disclaimer →
Related Coverage
Medically reviewed by Prof. Giorgi Pkhakadze, MD, MPH, PhD. Spotted an error? Contact the editorial team.
